| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972967 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5965581 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5978698 | MEDICURE | Angioplasty procedure using nonionic contrast media |
Oct, 2017
(6 years ago) | |
| US6136794 | MEDICURE | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan, 2019
(5 years ago) | |
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(11 months ago) | |
Aggrastat is owned by Medicure.
Aggrastat contains Tirofiban Hydrochloride.
Aggrastat has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Aggrastat are:
- US5972967
- US5733919
- US5965581
- US5978698
- US6136794
- US6770660
- US5733919
Aggrastat was authorised for market use on 17 May, 2002.
Aggrastat is available in solution;injection, injectable;injection, solution;intravenous dosage forms.
Aggrastat can be used as a dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.
The generics of Aggrastat are possible to be released after 01 May, 2023.
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 May, 2002
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: SOLUTION;INTRAVENOUS; SOLUTION;INJECTION; INJECTABLE;INJECTION
AGGRASTAT family patents
